<abstract xmlns="http://www.w3.org/1999/xhtml"><sec><h3>Background</h3><p>It is recognised that systemic inflammation plays an important role in the development and progression of lung cancer. Several affordable biomarkers could be used to evaluate systemic inflammation: neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and erythrocyte sedimentation rate (ESR). These biomarkers may be linked with survival in lung cancer.</p></sec><sec><h3>Aim</h3><p>To assess the relation between systemic inflammation evaluated by NLR, PLR and ESR, tumour nodes metastasis (TNM) staging and negative outcome in lung cancer.</p></sec><sec><h3>Materials and methods</h3><p>Patients with lung cancer were classified (7th TNM lung cancer staging) into two groups: Group A (resectable stages) and Group B (nonresectable stages). Each group was divided into two subsets: survivors (As, Bs) and deceased (Ad, Bd) patients. Complete blood count (CBC) and ESR were determined. NLR and PLR were calculated. NLR, PLR and ESR values were compared between the two groups and their subsets.</p></sec><sec><h3>Results</h3><p>102 consecutive patients completed the protocol. In Group A (31 patients): NLR: 2.74 (0.87–12.94), PLR: 33.95 (21.61–416.66), ESR: 35 mm/h (6–135). Subgroup As: NLR: 2.36 (0.87–8.36), PLR: 138.82 (21.61–416.66), ESR: 15 mm/h (6–110). Subgroup Ad: NLR: 2.77 (1.25–12.94), PLR: 132.57 (41.11–371.17), ESR: 62 mm/h (11–135). In Group B (71 patients): NLR: 3.51(0.76–25.60), PLR: 170.37 (3.38–651.25), ESR:40 mm/h (3–120). Subgroup Bs: NLR: 1.40 (1.32–1.73), PLR: 112.89 (91.14–140.54), ESR: 31 mm/h (9–90). Subgroup Bd: NLR: 3.59 (0.70–25.60), PLR: 183.50 (3.38–651.25), ESR: 44 mm/h (3–120). NLR and PLR values were significantly higher (p: 0.04; p: 0.05) in Group B versus Group A. No significant difference was noted for ESR values between the two groups. In patients with nonresectable stages who were deceased (subgroup Bd), NLR and PLR values were significantly higher (p: 0.01; p: 0.03) versus survivals. In patients with resectable stages who were deceased (subgroup Ad), only the ESR value was significantly higher versus survivals.</p></sec><sec><h3>Conclusions</h3><p>Systemic inflammation assessed by affordable biomarkers as NLR and PLR is more prominent in advanced, nonresectable lung cancer. It may be a contributor, along with TNM staging, to the poor outcome of patients with nonresectable lung cancer.</p></sec><sec><h3>Clinical implication</h3><p>NLR and PLR may represent a valuable additional tool in the clinical management of patients with nonresectable lung cancer.</p></sec></abstract>

BackgroundIt is recognised that systemic inflammation plays an important role in the development and progression of lung cancer. Several affordable biomarkers could be used to evaluate systemic inflammation: neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and erythrocyte sedimentation rate (ESR). These biomarkers may be linked with survival in lung cancer.AimTo assess the relation between systemic inflammation evaluated by NLR, PLR and ESR, tumour nodes metastasis (TNM) staging and negative outcome in lung cancer.Materials and methodsPatients with lung cancer were classified (7th TNM lung cancer staging) into two groups: Group A (resectable stages) and Group B (nonresectable stages). Each group was divided into two subsets: survivors (As, Bs) and deceased (Ad, Bd) patients. Complete blood count (CBC) and ESR were determined. NLR and PLR were calculated. NLR, PLR and ESR values were compared between the two groups and their subsets.Results102 consecutive patients completed the protocol. In Group A (31 patients): NLR: 2.74 (0.87–12.94), PLR: 33.95 (21.61–416.66), ESR: 35 mm/h (6–135). Subgroup As: NLR: 2.36 (0.87–8.36), PLR: 138.82 (21.61–416.66), ESR: 15 mm/h (6–110). Subgroup Ad: NLR: 2.77 (1.25–12.94), PLR: 132.57 (41.11–371.17), ESR: 62 mm/h (11–135). In Group B (71 patients): NLR: 3.51(0.76–25.60), PLR: 170.37 (3.38–651.25), ESR:40 mm/h (3–120). Subgroup Bs: NLR: 1.40 (1.32–1.73), PLR: 112.89 (91.14–140.54), ESR: 31 mm/h (9–90). Subgroup Bd: NLR: 3.59 (0.70–25.60), PLR: 183.50 (3.38–651.25), ESR: 44 mm/h (3–120). NLR and PLR values were significantly higher (p: 0.04; p: 0.05) in Group B versus Group A. No significant difference was noted for ESR values between the two groups. In patients with nonresectable stages who were deceased (subgroup Bd), NLR and PLR values were significantly higher (p: 0.01; p: 0.03) versus survivals. In patients with resectable stages who were deceased (subgroup Ad), only the ESR value was significantly higher versus survivals.ConclusionsSystemic inflammation assessed by affordable biomarkers as NLR and PLR is more prominent in advanced, nonresectable lung cancer. It may be a contributor, along with TNM staging, to the poor outcome of patients with nonresectable lung cancer.Clinical implicationNLR and PLR may represent a valuable additional tool in the clinical management of patients with nonresectable lung cancer.

Systemic inflammation, TNM staging and survival in patients with lung cancer

”Dr. Carol Davila” Central Military Emergency Universitary Hospital Bucharest

Carol Davila University of Medicine and Pharmacy

Pneumologia

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Relația dintre inflamația sistemică, stadializarea TNM și suprviețuire la pacienții cu diagnostic de cancer bronhopulmonar

BackgroundIt is recognised that systemic inflammation plays an important role in the development and progression of lung cancer. Several affordable biomarkers...

	NLR	PLR	ESR (mm/h)
Subset As (survivors, n=11)	2,36 (0,87–8.36)	138,82 (21,61–416,66)	15 (6–110)
Subset Ad (deceased, n=20)	2,77 (1,25–12,94)	132,57 (41,11–371,17)	62 (11–135)
Subset Bs (survivors, n=8)	1,40 (1,32–1,73)	112,89 (91,14–140,54)	31 (9–90)
Subset Bd (deceased, n=63)	3,59 (0,70–26,60)	183,50 (3,38–651,25)	44 (3–120)

102 patients	Age (years)	History of smoking (No, %)	PA (No)	Ne (/mm³)	Ly (/mm³)	PI (/mm³)	NLR	PLR	ESR (mm/h)
Group A (resectable stages) 31 (23 men)	65 (51–83)	23 74,2%	40 (3–100)	6380 (2600-22.000)	2000 (1020-13.600)	294.000 (111.000–709.000)	2,74 (0,87–12,94)	133,95 (21,61–416,66)	35 (6–135)
Group B (nonresectable stages) 71 (63 men)	67 (37–88)	60 84,5%	40 (4–90)	6450 (1800–27.892)	1800 (500–15.700)	327.000 (23.000–661.000)	3,51 (0,76–25,60)	170,37 (3.38–651,25)	40 (3–120)

Systemic inflammation, TNM staging and survival in patients with lung cancer

Article Category: Original Papers

Online veröffentlicht: 31. Dez. 2020

Seitenbereich: 81 - 86

DOI: https://doi.org/10.2478/pneum-2020-0016

Schlüsselwörter
lung cancer, systemic inflammation, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio

© 2020 Ionela Erhan et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Figure 1

Figure 2

Figure 3

The value of NLR, PLR and ESR in the two subsets of Group A (n=31) and Group B (n=71)

Characteristic of the patients with resectable (Group A) and nonresectable (Group B) lung cancer

Systemic inflammation, TNM staging and survival in patients with lung cancer

Article Category: Original Papers

Online veröffentlicht: 31. Dez. 2020

Seitenbereich: 81 - 86

DOI: https://doi.org/10.2478/pneum-2020-0016

Schlüsselwörterlung cancer, systemic inflammation, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio

© 2020 Ionela Erhan et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Figure 1

Figure 2

Figure 3

The value of NLR, PLR and ESR in the two subsets of Group A (n=31) and Group B (n=71)

Characteristic of the patients with resectable (Group A) and nonresectable (Group B) lung cancer

Schlüsselwörter
lung cancer, systemic inflammation, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio